180 related articles for article (PubMed ID: 31502695)
1. Ontogeny and the Application of Pharmacogenomics to Pediatric Drug Development.
Green D
J Clin Pharmacol; 2019 Sep; 59 Suppl 1():S82-S86. PubMed ID: 31502695
[TBL] [Abstract][Full Text] [Related]
2. Pharmacogenomic information in FDA-approved drug labels: Application to pediatric patients.
Green DJ; Mummaneni P; Kim IW; Oh JM; Pacanowski M; Burckart GJ
Clin Pharmacol Ther; 2016 Jun; 99(6):622-32. PubMed ID: 26693845
[TBL] [Abstract][Full Text] [Related]
3. Pharmacogenomic biomarkers in drug labels: what do they tell us?
Tutton R
Pharmacogenomics; 2014 Feb; 15(3):297-304. PubMed ID: 24533709
[TBL] [Abstract][Full Text] [Related]
4. Applications of pharmacogenomics in regulatory science: a product life cycle review.
Tan-Koi WC; Leow PC; Teo YY
Pharmacogenomics J; 2018 May; 18(3):359-366. PubMed ID: 29205206
[TBL] [Abstract][Full Text] [Related]
5. Study of pharmacogenomic information in FDA-approved drug labeling to facilitate application of precision medicine.
Mehta D; Uber R; Ingle T; Li C; Liu Z; Thakkar S; Ning B; Wu L; Yang J; Harris S; Zhou G; Xu J; Tong W; Lesko L; Fang H
Drug Discov Today; 2020 May; 25(5):813-820. PubMed ID: 32032705
[TBL] [Abstract][Full Text] [Related]
6. Learning from product labels and label changes: how to build pharmacogenomics into drug-development programs.
Surh LC; Pacanowski MA; Haga SB; Hobbs S; Lesko LJ; Gottlieb S; Papaluca-Amati M; Patterson SD; Hughes AR; Kim MJ; Close SL; Mosteller M; Zineh I; Dechairo B; Cohen NA
Pharmacogenomics; 2010 Dec; 11(12):1637-47. PubMed ID: 21142906
[TBL] [Abstract][Full Text] [Related]
7. Similarities and differences between US and Japan as to pharmacogenomic biomarker information in drug labels.
Otsubo Y; Asahina Y; Noguchi A; Sato Y; Ando Y; Uyama Y
Drug Metab Pharmacokinet; 2012; 27(1):142-9. PubMed ID: 22201121
[TBL] [Abstract][Full Text] [Related]
8. Pharmacogenomic information from CPIC and DPWG guidelines and its application on drug labels.
Yoon DY; Lee S; Ban MS; Jang IJ; Lee S
Transl Clin Pharmacol; 2020 Dec; 28(4):189-198. PubMed ID: 33425802
[TBL] [Abstract][Full Text] [Related]
9. Pharmacogenomic Biomarkers: an FDA Perspective on Utilization in Biological Product Labeling.
Schuck RN; Grillo JA
AAPS J; 2016 May; 18(3):573-7. PubMed ID: 26912182
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenomic biomarkers: Interpretation of information included in United States and Japanese drug labels.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2018 Aug; 43(4):500-506. PubMed ID: 29722046
[TBL] [Abstract][Full Text] [Related]
11. Pharmacogenomic biomarker information in FDA-approved paediatric drug labels.
Kim T; Han N; Sohn M; Oh JM; Lee EK; Ji E; Kim IW
Basic Clin Pharmacol Toxicol; 2015 May; 116(5):438-44. PubMed ID: 25348905
[TBL] [Abstract][Full Text] [Related]
12. Pharmacogenomic information in the Warning section of drug labels: A comparison between labels in the United States and those in five other countries/regions.
Imatoh T; Sai K; Saito Y
J Clin Pharm Ther; 2018 Aug; 43(4):493-499. PubMed ID: 29682780
[TBL] [Abstract][Full Text] [Related]
13. Drug Safety in Labeling for Pediatric Drug Development and Dose Selection in Submissions to the US Food and Drug Administration.
Kim C; Park K; McMahon AW; Green FG; Green DJ; Burckart GJ
J Clin Pharmacol; 2021 Jun; 61 Suppl 1():S133-S140. PubMed ID: 34185899
[TBL] [Abstract][Full Text] [Related]
14. Pharmacogenomic biomarker information differences between drug labels in the United States and Hungary: implementation from medical practitioner view.
Varnai R; Szabo I; Tarlos G; Szentpeteri LJ; Sik A; Balogh S; Sipeky C
Pharmacogenomics J; 2020 Jun; 20(3):380-387. PubMed ID: 31787752
[TBL] [Abstract][Full Text] [Related]
15. Children, drugs, and the Food and Drug Administration: studies of pediatric drugs are beginning to catch up.
Ward RM
Pediatr Ann; 2001 Apr; 30(4):189-94. PubMed ID: 11303433
[No Abstract] [Full Text] [Related]
16. Pediatric drug labeling: improving the safety and efficacy of pediatric therapies.
Roberts R; Rodriguez W; Murphy D; Crescenzi T
JAMA; 2003 Aug; 290(7):905-11. PubMed ID: 12928467
[TBL] [Abstract][Full Text] [Related]
17. Variability of Pharmacogenomics Information in Drug Labels Approved by Different Agencies and its Ethical Implications.
Güner MD; Ekmekci PE; Kurtoglu B
Curr Drug Saf; 2022; 17(1):47-53. PubMed ID: 34315387
[TBL] [Abstract][Full Text] [Related]
18. Personalized Medicine in the Paediatric Population: The Balance Between Pharmacogenetic Progress and Bioethics.
Schiavone S; Neri M; Pomara C; Riezzo I; Trabace L; Turillazzi E
Curr Pharm Biotechnol; 2017; 18(3):253-262. PubMed ID: 28176639
[TBL] [Abstract][Full Text] [Related]
19. Pharmacogenomic information in drug labels: European Medicines Agency perspective.
Ehmann F; Caneva L; Prasad K; Paulmichl M; Maliepaard M; Llerena A; Ingelman-Sundberg M; Papaluca-Amati M
Pharmacogenomics J; 2015 Jun; 15(3):201-10. PubMed ID: 25707393
[TBL] [Abstract][Full Text] [Related]
20. Differences in pharmacogenomic biomarker information in package inserts from the United States, the United Kingdom and Japan.
Shimazawa R; Ikeda M
J Clin Pharm Ther; 2013 Dec; 38(6):468-75. PubMed ID: 23895776
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
